Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9293MR)

This product GTTS-WQ9293MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9293MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4687MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ14548MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ14262MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ12901MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ13289MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ4161MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ678MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ11420MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW